HEADER TRANSFERASE 17-MAY-11 2YIX TITLE TRIAZOLOPYRIDINE INHIBITORS OF P38 COMPND MOL_ID: 1; COMPND 2 MOLECULE: MITOGEN-ACTIVATED PROTEIN KINASE 14; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: RESIDUES 4-354; COMPND 5 SYNONYM: P38 KINASE, MAP KINASE 14, MAPK 14, CYTOKINE SUPPRESSIVE COMPND 6 ANTI-INFLAMMATORY DRUG-BINDING PROTEIN, CSAID-BINDING PROTEIN, COMPND 7 CSBP, MAP KINASE MXI2, MAX-INTERACTING PROTEIN 2, COMPND 8 MITOGEN-ACTIVATED PROTEIN KINASE P38 ALPHA, MAP KINASE P38 ALPHA, COMPND 9 SAPK2A; COMPND 10 EC: 2.7.11.24; COMPND 11 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_TAXID: 9606; SOURCE 4 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 5 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS PHOSPHORYLATION, SERINE/THREONINE-PROTEIN KINASE, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR D.S.MILLAN,M.ANDERSON,M.E.BUNNAGE,J.L.BURROWS,K.J.BUTCHER,P.G.DODD, AUTHOR 2 T.J.EVANS,D.A.FAIRMAN,S.HAN,S.J.HUGHES,S.L.IRVING,I.C.KILTY, AUTHOR 3 A.LEMAITRE,R.A.LEWTHAWAITE,A.MAHKE,E.MARR,J.P.MATHIAS,J.PHILIP, AUTHOR 4 C.PHILLIPS,R.T.SMITH,M.H.STEFANIAK,M.YEADON REVDAT 1 30-NOV-11 2YIX 0 JRNL AUTH D.S.MILLAN,M.E.BUNNAGE,J.L.BURROWS,K.J.BUTCHER,P.G.DODD, JRNL AUTH 2 T.J.EVANS,D.A.FAIRMAN,S.J.HUGHES,I.C.KILTY,A.LEMAITRE, JRNL AUTH 3 R.A.LEWTHWAITE,A.MAHNKE,J.P.MATHIAS,J.PHILIP,R.T.SMITH, JRNL AUTH 4 M.H.STEFANIAK,M.YEADON,C.PHILLIPS JRNL TITL DESIGN AND SYNTHESIS OF INHALED P38 INHIBITORS FOR THE JRNL TITL 2 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. JRNL REF J.MED.CHEM. V. 54 7797 2011 JRNL REFN ISSN 0022-2623 JRNL PMID 21888439 JRNL DOI 10.1021/JM200677B REMARK 2 REMARK 2 RESOLUTION. 2.30 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.9.6 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SMART,VONRHEIN,WOMACK, REMARK 3 : MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.30 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 24.75 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.0 REMARK 3 COMPLETENESS FOR RANGE (%) : 96.40 REMARK 3 NUMBER OF REFLECTIONS : 21609 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.1959 REMARK 3 R VALUE (WORKING SET) : 0.1932 REMARK 3 FREE R VALUE : 0.2472 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.12 REMARK 3 FREE R VALUE TEST SET COUNT : 1106 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 11 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.30 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.41 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 96.40 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2671 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2474 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2527 REMARK 3 BIN R VALUE (WORKING SET) : 0.2450 REMARK 3 BIN FREE R VALUE : 0.2899 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.39 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 144 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2834 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 26 REMARK 3 SOLVENT ATOMS : 273 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 44.05 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 37.39 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 4.8458 REMARK 3 B22 (A**2) : 3.3912 REMARK 3 B33 (A**2) : -8.2370 REMARK 3 B12 (A**2) : 0.0000 REMARK 3 B13 (A**2) : 0.0000 REMARK 3 B23 (A**2) : 0.0000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.284 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.295 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.226 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.264 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.219 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.9332 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.9018 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 2926 ; 2.00 ; HARMONIC REMARK 3 BOND ANGLES : 3974 ; 2.00 ; HARMONIC REMARK 3 TORSION ANGLES : 1012 ; 2.00 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 81 ; 2.00 ; HARMONIC REMARK 3 GENERAL PLANES : 421 ; 5.00 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 2926 ; 20.00 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : 1 ; 5.00 ; SEMIHARMONIC REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 377 ; 5.00 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 3414 ; 4.00 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.13 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 2.97 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 18.56 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2YIX COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 17-MAY-11. REMARK 100 THE PDBE ID CODE IS EBI-48323. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : NULL REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : NULL REMARK 200 DETECTOR MANUFACTURER : NULL REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : NULL REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 21609 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.30 REMARK 200 RESOLUTION RANGE LOW (A) : 25.00 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.0 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 96.0 REMARK 200 DATA REDUNDANCY : 2.8 REMARK 200 R MERGE (I) : 0.08 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 12.00 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: OTHER REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NONE REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 59.35 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.03 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 22.97200 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 61.29000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 43.26150 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 61.29000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 22.97200 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 43.26150 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 OD1 ASN A 201 OG1 THR A 203 2.18 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 ASP A 354 C ASP A 354 O 2.274 REMARK 500 ASP A 354 C ASP A 354 OXT 1.571 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ASP A 354 CA - C - O ANGL. DEV. = -19.8 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ARG A 57 55.24 39.49 REMARK 500 ASN A 100 -42.18 -140.61 REMARK 500 ASN A 115 14.36 -66.69 REMARK 500 ILE A 116 -54.88 -129.02 REMARK 500 VAL A 117 75.97 -115.39 REMARK 500 CYS A 119 -2.69 57.86 REMARK 500 ARG A 149 -12.91 74.29 REMARK 500 LEU A 289 56.42 -91.72 REMARK 500 PRO A 314 0.63 -65.45 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE YIX A1355 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2BAJ RELATED DB: PDB REMARK 900 P38ALPHA BOUND TO PYRAZOLOUREA REMARK 900 RELATED ID: 1WFC RELATED DB: PDB REMARK 900 STRUCTURE OF APO, UNPHOSPHORYLATED, P38 MITOGEN REMARK 900 ACTIVATEDPROTEIN KINASE P38 (P38 MAP KINASE) THE REMARK 900 MAMMALIAN HOMOLOGUEOF THE YEAST HOG1 PROTEIN REMARK 900 RELATED ID: 1W7H RELATED DB: PDB REMARK 900 P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL REMARK 900 MOLECULE INHIBITOR REMARK 900 RELATED ID: 1WBO RELATED DB: PDB REMARK 900 FRAGMENT BASED P38 INHIBITORS REMARK 900 RELATED ID: 1KV2 RELATED DB: PDB REMARK 900 HUMAN P38 MAP KINASE IN COMPLEX WITH BIRB 796 REMARK 900 RELATED ID: 1BMK RELATED DB: PDB REMARK 900 THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655 REMARK 900 RELATED ID: 1YQJ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A REMARK 900 SELECTIVEPYRIDAZINE INHIBITOR REMARK 900 RELATED ID: 1BL7 RELATED DB: PDB REMARK 900 THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025 REMARK 900 RELATED ID: 1ZYJ RELATED DB: PDB REMARK 900 HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A REMARK 900 RELATED ID: 1A9U RELATED DB: PDB REMARK 900 THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580 REMARK 900 RELATED ID: 1WBT RELATED DB: PDB REMARK 900 IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS REMARK 900 USING FRAGMENT-BASED LEAD GENERATION. REMARK 900 RELATED ID: 2I0H RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38ALPHA IN COMPLEX WITH REMARK 900 ANARYLPYRIDAZINONE REMARK 900 RELATED ID: 2BAQ RELATED DB: PDB REMARK 900 P38ALPHA BOUND TO RO3201195 REMARK 900 RELATED ID: 1WBV RELATED DB: PDB REMARK 900 IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS REMARK 900 USING FRAGMENT-BASED LEAD GENERATION. REMARK 900 RELATED ID: 1ZZ2 RELATED DB: PDB REMARK 900 TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING REMARK 900 ACOMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT REMARK 900 BINDINGMODES REMARK 900 RELATED ID: 1DI9 RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE REMARK 900 INCOMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-6,7- REMARK 900 DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 1W83 RELATED DB: PDB REMARK 900 P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL REMARK 900 MOLECULE INHIBITOR REMARK 900 RELATED ID: 1BL6 RELATED DB: PDB REMARK 900 THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995 REMARK 900 RELATED ID: 1M7Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH REMARK 900 ADIHYDROQUINAZOLINONE INHIBITOR REMARK 900 RELATED ID: 1IAN RELATED DB: PDB REMARK 900 HUMAN P38 MAP KINASE INHIBITOR COMPLEX REMARK 900 RELATED ID: 1OZ1 RELATED DB: PDB REMARK 900 P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4- REMARK 900 AZAINDOLEINHIBITOR REMARK 900 RELATED ID: 1WBN RELATED DB: PDB REMARK 900 FRAGMENT BASED P38 INHIBITORS REMARK 900 RELATED ID: 2BAK RELATED DB: PDB REMARK 900 P38ALPHA MAP KINASE BOUND TO MPAQ REMARK 900 RELATED ID: 2BAL RELATED DB: PDB REMARK 900 P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE REMARK 900 RELATED ID: 1WBS RELATED DB: PDB REMARK 900 IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS REMARK 900 USING FRAGMENT-BASED LEAD GENERATION. REMARK 900 RELATED ID: 1OUY RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A REMARK 900 DIHYDROPYRIDO-PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1OUK RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH REMARK 900 APYRIDINYLIMIDAZOLE INHIBITOR REMARK 900 RELATED ID: 2Y8O RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A REMARK 900 MAPK DOCKING PEPTIDE REMARK 900 RELATED ID: 2YIS RELATED DB: PDB REMARK 900 TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE. REMARK 900 RELATED ID: 1R39 RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38ALPHA REMARK 900 RELATED ID: 1KV1 RELATED DB: PDB REMARK 900 P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1 REMARK 900 RELATED ID: 1WBW RELATED DB: PDB REMARK 900 IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS REMARK 900 USING FRAGMENT-BASED LEAD GENERATION. REMARK 900 RELATED ID: 1W82 RELATED DB: PDB REMARK 900 P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL REMARK 900 MOLECULE INHIBITOR REMARK 900 RELATED ID: 1R3C RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38ALPHA C162S MUTANT REMARK 900 RELATED ID: 1OVE RELATED DB: PDB REMARK 900 THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH REMARK 900 ADIHYDROQUINOLINONE REMARK 900 RELATED ID: 1ZZL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE REMARK 900 RELATED ID: 1W84 RELATED DB: PDB REMARK 900 P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL REMARK 900 MOLECULE INHIBITOR REMARK 900 RELATED ID: 2YIW RELATED DB: PDB REMARK 900 TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE DBREF 2YIX A 4 354 UNP Q16539 MK14_HUMAN 4 354 SEQRES 1 A 351 GLU ARG PRO THR PHE TYR ARG GLN GLU LEU ASN LYS THR SEQRES 2 A 351 ILE TRP GLU VAL PRO GLU ARG TYR GLN ASN LEU SER PRO SEQRES 3 A 351 VAL GLY SER GLY ALA TYR GLY SER VAL CYS ALA ALA PHE SEQRES 4 A 351 ASP THR LYS THR GLY LEU ARG VAL ALA VAL LYS LYS LEU SEQRES 5 A 351 SER ARG PRO PHE GLN SER ILE ILE HIS ALA LYS ARG THR SEQRES 6 A 351 TYR ARG GLU LEU ARG LEU LEU LYS HIS MET LYS HIS GLU SEQRES 7 A 351 ASN VAL ILE GLY LEU LEU ASP VAL PHE THR PRO ALA ARG SEQRES 8 A 351 SER LEU GLU GLU PHE ASN ASP VAL TYR LEU VAL THR HIS SEQRES 9 A 351 LEU MET GLY ALA ASP LEU ASN ASN ILE VAL LYS CYS GLN SEQRES 10 A 351 LYS LEU THR ASP ASP HIS VAL GLN PHE LEU ILE TYR GLN SEQRES 11 A 351 ILE LEU ARG GLY LEU LYS TYR ILE HIS SER ALA ASP ILE SEQRES 12 A 351 ILE HIS ARG ASP LEU LYS PRO SER ASN LEU ALA VAL ASN SEQRES 13 A 351 GLU ASP CYS GLU LEU LYS ILE LEU ASP PHE GLY LEU ALA SEQRES 14 A 351 ARG HIS THR ASP ASP GLU MET THR GLY TYR VAL ALA THR SEQRES 15 A 351 ARG TRP TYR ARG ALA PRO GLU ILE MET LEU ASN TRP MET SEQRES 16 A 351 HIS TYR ASN GLN THR VAL ASP ILE TRP SER VAL GLY CYS SEQRES 17 A 351 ILE MET ALA GLU LEU LEU THR GLY ARG THR LEU PHE PRO SEQRES 18 A 351 GLY THR ASP HIS ILE ASP GLN LEU LYS LEU ILE LEU ARG SEQRES 19 A 351 LEU VAL GLY THR PRO GLY ALA GLU LEU LEU LYS LYS ILE SEQRES 20 A 351 SER SER GLU SER ALA ARG ASN TYR ILE GLN SER LEU THR SEQRES 21 A 351 GLN MET PRO LYS MET ASN PHE ALA ASN VAL PHE ILE GLY SEQRES 22 A 351 ALA ASN PRO LEU ALA VAL ASP LEU LEU GLU LYS MET LEU SEQRES 23 A 351 VAL LEU ASP SER ASP LYS ARG ILE THR ALA ALA GLN ALA SEQRES 24 A 351 LEU ALA HIS ALA TYR PHE ALA GLN TYR HIS ASP PRO ASP SEQRES 25 A 351 ASP GLU PRO VAL ALA ASP PRO TYR ASP GLN SER PHE GLU SEQRES 26 A 351 SER ARG ASP LEU LEU ILE ASP GLU TRP LYS SER LEU THR SEQRES 27 A 351 TYR ASP GLU VAL ILE SER PHE VAL PRO PRO PRO LEU ASP HET YIX A1355 26 HETNAM YIX 1-ETHYL-3-(2-{[3-(1-METHYLETHYL)[1,2,4] HETNAM 2 YIX TRIAZOLO[4,3-A]PYRIDIN-6-YL]SULFANYL}BENZYL) HETNAM 3 YIX UREA HETSYN YIX CE-159167 FORMUL 2 YIX C19 H23 N5 O S FORMUL 3 HOH *273(H2 O) HELIX 1 1 GLY A 31 ALA A 34 5 4 HELIX 2 2 SER A 61 MET A 78 1 18 HELIX 3 3 SER A 95 PHE A 99 5 5 HELIX 4 4 THR A 123 ALA A 144 1 22 HELIX 5 5 LYS A 152 SER A 154 5 3 HELIX 6 6 ALA A 172 ASP A 177 5 6 HELIX 7 7 VAL A 183 TYR A 188 1 6 HELIX 8 8 ALA A 190 LEU A 195 1 6 HELIX 9 9 THR A 203 GLY A 219 1 17 HELIX 10 10 ASP A 227 GLY A 240 1 14 HELIX 11 11 GLY A 243 ILE A 250 1 8 HELIX 12 12 SER A 252 SER A 261 1 10 HELIX 13 13 ASN A 269 PHE A 274 1 6 HELIX 14 14 ASN A 278 LEU A 289 1 12 HELIX 15 15 ASP A 292 ARG A 296 5 5 HELIX 16 16 THR A 298 ALA A 304 1 7 HELIX 17 17 HIS A 305 ALA A 309 5 5 HELIX 18 18 GLN A 325 ARG A 330 5 6 HELIX 19 19 LEU A 333 SER A 347 1 15 SHEET 1 AA 2 PHE A 8 LEU A 13 0 SHEET 2 AA 2 THR A 16 PRO A 21 -1 O THR A 16 N LEU A 13 SHEET 1 AB 5 TYR A 24 PRO A 29 0 SHEET 2 AB 5 VAL A 38 ASP A 43 -1 O ALA A 40 N SER A 28 SHEET 3 AB 5 ARG A 49 LYS A 54 -1 O VAL A 50 N ALA A 41 SHEET 4 AB 5 TYR A 103 HIS A 107 -1 O LEU A 104 N LYS A 53 SHEET 5 AB 5 ASP A 88 PHE A 90 -1 O ASP A 88 N VAL A 105 SHEET 1 AC 3 ALA A 111 ASP A 112 0 SHEET 2 AC 3 LEU A 156 VAL A 158 -1 O VAL A 158 N ALA A 111 SHEET 3 AC 3 LEU A 164 ILE A 166 -1 O LYS A 165 N ALA A 157 SITE 1 AC1 14 LYS A 53 GLU A 71 LEU A 74 LEU A 75 SITE 2 AC1 14 ILE A 84 THR A 106 HIS A 107 LEU A 108 SITE 3 AC1 14 MET A 109 GLY A 110 ALA A 111 LEU A 167 SITE 4 AC1 14 ASP A 168 PHE A 169 CRYST1 45.944 86.523 122.580 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.021766 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011558 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008158 0.00000